McMaster test detects the most prevalent respiratory viruses

Diagnosing a nasty cough is now a lot easier thanks to a new test developed at McMaster University, which has just been approved by U.S. Food and Drug Administration (FDA) for use in the United States.

This new test simultaneously detects the most prevalent respiratory viruses, including flu and the common cold, helping doctors more accurately diagnose patients. It was developed by McMaster virologist Dr. James Mahony, in conjunction with Luminex Molecular Diagnostics (formerly TM Biosciences).

The xTAG™ Respiratory Viral Panel can detect most common respiratory viruses in a few hours. Traditional testing for this many viruses requires multiple individual diagnostic tests to be performed on a patient sample and can take several days to provide a thorough diagnosis. The speed and reliability of xTAG™ RVP will help physicians provide appropriate treatment, and prevent inappropriate antibiotic use that has contributed to the creation of "superbugs."

"Respiratory viruses affect millions of people each year and can lead to serious complications such as bacterial super infections and pneumonia. The RVP test allows healthcare providers to more rapidly and accurately detect infected patients and take appropriate measures to treat and reduce the spread of the disease," said Mahony, who is the director of the McMaster University Regional Virology and Chlamydiology Laboratory at St. Joseph's Healthcare Hamilton and is a professor in the Department of Pathology and Molecular Medicine at McMaster.

The FDA approval allows U.S. laboratories to use the test to simultaneously detect and identify 12 viruses and viral subtypes that together are responsible for more than 85 percent of respiratory viral infections, including influenza A, influenza A-H1, influenza A-H3, influenza B, Adenovirus, respiratory syncytial virus (RSV) A and B, metapneumovirus, parainfluenza 1, 2, and 3, and rhinovirus.

The test is also CE ("Conformité Européenne") certified to detect and identify 20 viruses and viral subtypes in Europe, adding eight viruses and subtypes including SARS and influenza A H5 (the subtype associated with avian influenza). Luminex is currently working to get the panel certified for patient use in Canada, although it is already available for investigational use.

Development of the xTAG™ Respiratory Viral Panel began in May 2005, when the company signed an agreement with McMaster to collaborate on the development of the test panel. After the prototype was created and validated at McMaster in Mahony’s lab based t St. Joseph’s Healthcare, the panel was further developed and commercially launched by Luminex.

“It’s rewarding to see a McMaster technology enter the marketplace in a way that will directly improve the treatment of patients,” Elsie Quaite-Randall, executive director of the McMaster Industry Liaison Office (MILO). “This is a great example of a win-win collaboration that transformed great research into a product that benefits patients.”

Source: McMaster University

Related stories:

When it comes to putting, Tiger and Nicklaus might not have best advice
Golfers who heed the advice of instructors to keep their heads perfectly still while putting may be hampering their game, according to a study that examined coordination patterns. The research appears in the July issue of the Journal of Motor Behavior.
Self-moisturizing contact lenses, naturally
Even contact lenses are joining the trend to go green. Chemical engineering researchers at McMaster University have shown that a common fluid found in our bodies can be used as a natural moisturizing agent in contact lenses.
Woman aquires new accent after stroke
A woman in southern Ontario is one of the first cases in Canada of a rare neurological syndrome in which a person starts speaking with a different accent, McMaster University researchers report in the July issue of the Canadian Journal of Neurological Sciences.
New blood clot guidelines for pregnant women
Blood clot recommendations highlight challenges for pediatric and pre-surgery populations
New evidence-based guidelines address the prevention and management of thrombosis in key patient populations and reinforce recommendations related to the routine use of preventive therapies. Published as a supplement in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), Antithrombotic and Thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition was developed by an international panel of 90 experts and includes more than 700 of the most comprehensive recommendations related to the prevention, treatment, and long-term management of thrombotic disorders. The guidelines include chapters on the challenges in preventing and treating thrombosis in pregnant women and children, and on managing peri- and postoperative patients, while also reinforcing previous guidelines related to the routine use of preventive therapies, including aspirin.
Canada-India RFID project looks to improve traffic flow, reduce pollution
RFID technology may provide the key to better traffic management and improved pollution control in Canada, India and worldwide.
Mini subs to probe odd structures in BC lake
Single person submersibles have been called in to help scientists retrieve samples from a lake in northern British Columbia that may hold vital clues to the history of life on Earth and on other planets.
Brief, intense exercise benefits the heart
Short bursts of high intensity sprints -- known to benefit muscle and improve exercise performance—can improve the function and structure of blood vessels, in particular arteries that deliver blood to our muscles and heart, according to new research from McMaster University.
Famous Supernovae Still Echo Across the Milky Way
While walking home on November 11, 1572, astronomer Tycho Brahe idly glanced at the sky. He was surprised to see a bright star in the constellation Cassiopeia that hadn’t been there before. The new star, which we now know to be the result of a stellar explosion or supernova, grew brighter than Venus and was visible in daylight for about two weeks. It then slowly faded until vanishing in March 1574, 16 months after its discovery.

News discussion:

Medicine & Health news